The role of CDK4/6 inhibitors in early breast cancer
Miguel Gil-Gil,
Emilio Alba,
Joaquín Gavilá,
Juan de la Haba-Rodríguez,
Eva Ciruelos,
Pablo Tolosa,
Daniele Candini,
Antonio Llombart-Cussac
Affiliations
Miguel Gil-Gil
Institut Català d'Oncologia IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
Emilio Alba
Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
Joaquín Gavilá
Fundación Instituto Valenciano de Oncología, Valencia, Spain
Juan de la Haba-Rodríguez
Department of Medical Oncology, Hospital Universitario Reina Sofía, Instituto de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
Eva Ciruelos
Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
Pablo Tolosa
Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
Daniele Candini
Medical Department, Pfizer Oncology, Madrid, Spain
Antonio Llombart-Cussac
Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain; FISABIO, Universidad Católica de Valencia, Spain; Corresponding author. Department of Medical Oncology, Hospital Arnau de Vilanova, Calle de Sant Clement 12, 46015 Valencia, Spain.
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
